Fractyl Health, Inc. (GUTS)
NASDAQ: GUTS · Real-Time Price · USD
1.590
+0.100 (6.71%)
Jul 16, 2025, 2:22 PM - Market open
Fractyl Health Employees
Fractyl Health had 107 employees as of December 31, 2024. The number of employees increased by 5 or 4.90% compared to the previous year.
Employees
107
Change (1Y)
5
Growth (1Y)
4.90%
Revenue / Employee
$561
Profits / Employee
-$832,776
Market Cap
77.87M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 107 | 5 | 4.90% |
| Dec 31, 2023 | 102 | 19 | 22.89% |
| Dec 31, 2021 | 83 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
GUTS News
- 4 hours ago - Fractyl Health: Speculative Buy With Binary Risk - Seeking Alpha
- 23 days ago - Fractyl Health Reports Positive 3-Month REVEAL-1 Cohort Data Showing Revita® Sustained Weight Loss After GLP-1 Discontinuation, Supporting its Potential as a First-in-Class Weight Maintenance Therapy - GlobeNewsWire
- 23 days ago - Fractyl Health Presents New Data at the American Diabetes Association's 85th Scientific Sessions Demonstrating its Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Platform Prevents Obesity and Type 2 Diabetes in Preclinical Models - GlobeNewsWire
- 4 weeks ago - Fractyl Health Reinforces Intellectual Property Leadership in Metabolic Disease with Two New U.S. Patents Directed to Duodenal Resurfacing - GlobeNewsWire
- 4 weeks ago - Fractyl Health to Present New Preclinical Data from its Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Platform at the American Diabetes Association's 85th Scientific Sessions - GlobeNewsWire
- 6 weeks ago - Fractyl Health and Bariendo Sign Letter of Intent to Prepare for Potential Offering of Revita® Across its Bariatric and Metabolic Endoscopy Centers Nationwide - GlobeNewsWire
- 2 months ago - Fractyl Health Advances Rejuva® Gene Therapy Platform with Submission of First Clinical Trial Application Module in Europe for RJVA-001 in Type 2 Diabetes - GlobeNewsWire
- 2 months ago - Fractyl Health Unveils New Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Preclinical Data Highlighting Durable Potency and Safety with Limited Systemic GLP-1 Exposure at ASGCT 2025 - GlobeNewsWire